Previous 10 | Next 10 |
The South Africa Health Products Regulatory Authority has signed-off ImmunityBio's Phase 1 trial to evaluate its hAd5 T-cell vaccine, the company’s COVID-19 vaccine candidate.The same vaccine is currently being tested in a similar Phase 1 trial in the U.S., with no safety con...
After a ~9.9% rise in value yesterday, Sorrento Therapeutics (SRNE) has added another ~8.9% so far today, and an analyst from H.C. Wainwright estimates a price target of ~$30 for the stock, implying a ~275.0% upside to yesterday’s close.The analyst Ram Selvaraju pro...
NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBio's impressive pipeline. As the COVID-19 pandemic accelerates and new variants emerge, health agenci...
Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx N.V. (IFRX) -9...
NantKwest (NK) has climbed 36.2% in premarket trading as Piper Sandler reiterates its overweight rating on the company after yesterday’s announcement of the early interim results yesterday for survival rates in metastatic pancreatic cancer trials.With a primary endpoint of ov...
Express (EXPR) +62% as company lines up new financing.DPW Holdings (DPW) +57% as pre-orders for residential level 2 EV chargers have begun on Amazon.Pingtan Marine Enterprise (PME) +43% on announcing FY 2021 guidance.ZW Data Action Technologies (CNET) +38%. after the company wa...
NantKwest (NK) +22.7% post-market after saying early interim results of its PD-L1 t-haNK protocols showed median survival rates more than doubled the historic rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists.The company says the tria...
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelu...
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39 th Annual J.P. Morgan Healthcare Conference. He will make a for...
NEW YORK, NY / ACCESSWIRE / December 30, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: NantKwest, Inc. (NASDAQ: NK ) relating to i...
News, Short Squeeze, Breakout and More Instantly...
NantKwest Company Name:
NK Stock Symbol:
NASDAQ Market:
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...